Find out about financial assistance for patients
For US residents only.
Overall response and duration of response
In a clinical trial, ZYKADIA® (ceritinib) was shown to shrink or slow the growth of tumors. In this trial, 163 patients with ALK+ metastatic NSCLC who had taken the medicine crizotinib, but their NSCLC worsened or they could not tolerate taking crizotinib, were treated with ZYKADIA.
Of those who responded, 1.2% of patients had a complete response to treatment (which is not the same as being cured) and 53.4% of patients had a partial response. This means that in these patients the amount or spread of cancer decreased or tumors shrank. Response to treatment lasted a median of 7.4 months.
You and your doctor need to discuss the possible benefits and risks of treatment with ZYKADIA, taking into account your medical history and current medications.
ZYKADIA can cause serious side effects in some people. Serious side effects associated with ZYKADIA include stomach and intestinal problems, liver injury, severe or life-threatening swelling of the lungs, and either very slow, very fast, or abnormal heartbeats. People who have diabetes or glucose intolerance, or who take a corticosteroid medicine, have an increased risk of high blood sugar with ZYKADIA. ZYKADIA can cause pancreatitis that has led to death.
Understand your disease, treatment options, and what you may expect while taking ZYKADIA® (ceritinib)